What are the common and serious adverse drug reactions of alprazolam (Xanax)?

Alprazolam Adverse Drug Reactions

Alprazolam causes significant sedation, cognitive impairment, and carries serious risks of dependence, withdrawal, respiratory depression (especially with opioids), and paradoxical behavioral reactions that can be life-threatening. 1

Common Adverse Reactions

Nervous System Effects (Most Frequent)

• Drowsiness/sedation occurs in 41-77% of patients depending on indication (41% in generalized anxiety disorder, 77% in panic disorder versus 22-43% with placebo) 1
• Cognitive impairment is substantial: memory impairment (33%), cognitive disorder (29%), and confusional state (10%) in panic disorder trials 1
• Light-headedness (21%), dizziness (2%), and impaired coordination (40% in panic disorder) are common 1
• Fatigue affects 49% of panic disorder patients 1

Gastrointestinal Effects

• Dry mouth (15%), constipation (26% in panic disorder), and increased salivation (4-6%) 1

Other Common Effects

• Weight changes: both weight gain (27%) and weight loss (23%) reported in panic disorder 1
• Appetite changes: increased (33%) or decreased (28%) appetite 1
• Sexual dysfunction: decreased libido (14%), sexual dysfunction (7%) 1

Important caveat: These sedative effects may persist into the next day, impairing driving ability up to 12.5 hours after nighttime administration of 2 mg alprazolam, even when patients are unaware of their impairment 2

Serious and Life-Threatening Adverse Reactions

Respiratory Depression

• When combined with opioids, alcohol, or other CNS depressants, alprazolam can cause severe respiratory depression, coma, and death 1
• Deaths have been reported in patients with severe pulmonary disease shortly after alprazolam initiation 1

Paradoxical Behavioral Reactions (Rare but Serious)

• Agitation, rage, irritability, aggressive or hostile behavior, hallucinations, and stimulation have been reported 1
• Mania or hypomania can occur 1
• Patients with borderline personality disorder, prior violent/aggressive behavior, or substance abuse history are at higher risk for these paradoxical reactions 1
• Worsening of post-traumatic stress disorder symptoms (irritability, hostility, intrusive thoughts) during discontinuation 1

Severe Withdrawal Reactions

• Abrupt discontinuation can cause life-threatening withdrawal: seizures, severe mental status changes, depression, hallucinations, suicidal thoughts, and delirium 1
• Protracted withdrawal syndrome can last weeks to over 12 months with symptoms including anxiety, insomnia, tremors, and sensory disturbances 1

Other Serious Reactions

• Acute intoxication, hepatitis, hepatic failure, amnesia, and depression 3, 1
• Stevens-Johnson syndrome, angioedema 1
• Suicidal ideation in patients with depression 1

Neonatal Effects

• Use during pregnancy causes neonatal sedation (respiratory depression, lethargy, hypotonia) and withdrawal symptoms (hyperreflexia, irritability, tremors, feeding difficulties) 1

Discontinuation-Emergent Symptoms

Upon tapering or discontinuation, the following symptoms occur at high rates (>5% and greater than placebo) 1:

• Insomnia (29.5%), anxiety (19.2%), light-headedness (19.3%)
• Abnormal involuntary movements (17.3%), headache (17%)
• Nausea/vomiting (16.5%), diarrhea (13.6%)
• Weight loss (13.3%), sweating (14.4%), tachycardia (12.2%)

Context from Broader Evidence

The American College of Physicians and American Academy of Sleep Medicine guidelines note that benzodiazepines (including alprazolam when used for insomnia) are associated with dementia, fractures, major injuries, and possibly cancer in observational studies 4. A 5-fold increase in memory loss and confusion, 3-fold increase in falls, and 4-fold increase in morning sedation occur in older adults 4.

Alprazolam has unique abuse and dependence liability due to its rapid onset and short half-life, making withdrawal particularly challenging 5. In clinical trials, potentially serious reactions occurred in 10 of 263 patients (3.8%), and adverse reactions leading to discontinuation occurred in 21% versus 0% with placebo 3, 6.

Clinical Implications

• Monitor all patients closely for sedation, cognitive impairment, and behavioral changes
• Never combine with opioids except when no alternatives exist 1
• Screen for substance abuse history, borderline personality disorder, and violent behavior before prescribing 1
• Always taper slowly when discontinuing—never stop abruptly 1
• Warn patients about next-day driving impairment even 12+ hours after nighttime dosing 2
• Use lower doses in women and elderly patients due to prolonged drug levels 4